[Affordable gene therapies?]

IF 0.6 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

M S-medecine Sciences Pub Date : 2025-02-01 Epub Date: 2025-03-03 DOI:10.1051/medsci/2025017

Bertrand Jordan

引用次数: 0

Abstract

Twenty gene therapies have now been approved in the USA by the FDA, but their stratospheric price tag (often above one million USD per patient) makes them essentially unaffordable for most. A systematic study of the various steps involved in the development and manufacture of these therapies, undertaken (among others) by the Innovative Genomics Institute in California, shows that the cost could be reduced up to tenfold without major legislative changes, and offers hope for affordable genetic therapies.

查看原文本刊更多论文

[负担得起的基因疗法？］

美国食品和药物管理局（FDA）现已批准了 20 种基因疗法，但其昂贵的价格（每名患者通常超过 100 万美元）使大多数人根本无法负担。加利福尼亚创新基因组学研究所（Innovative Genomics Institute）等机构对这些疗法的开发和生产过程中的各个环节进行了系统研究，结果表明，如果不对立法进行重大修改，成本最多可降低十倍，这为人们提供了负担得起的基因疗法的希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

M S-medecine Sciences 医学-医学：研究与实验

CiteScore

0.80

自引率

14.30%

发文量

182

审稿时长

4-8 weeks

期刊介绍： m/s offers high-quality review articles in French, covering all areas of biomedical and health research, in a monthly magazine format (10 issues / year). m/s is read by the whole French-speaking community, in France but also in Belgium, Switzerland, Canada, Morocco, Algeria, Tunisia etc. m/s is not a primary publication, and thus will not consider unpublished data. Most articles are invited by the Editors, but spontaneous proposals are welcomed. Each issue combines news and views on the most recent scientific publications, as well as broadly accessible and updated review articles on a specific topic, and essays on science and society, history of science, public health, or reactions to published articles. Each year, m/s also publishes one or two thematic issues focused on a research topic of high interest. All review articles and essays are peer-reviewed.